Recombinant Rat LAG3 Protein(HEK293)，His

LAG3 (Lymphocyte Activation Gene 3) is an immune checkpoint receptor that plays a crucial role in regulating T cell function and maintaining immune tolerance. It is primarily expressed on activated T cells, regulatory T cells, and some antigen-presenting cells. Research has shown that LAG3 acts as a suppressive mechanism that dampens immune responses, particularly in the context of cancer and chronic infections, making it an important target for immunotherapy. The development of LAG3-Fc fusion proteins, where the extracellular domain of LAG3 is fused to the Fc region of an immunoglobulin, has been a significant focus in recent studies. These recombinant proteins can bind to MHC class II molecules, blocking LAG3's interaction with its ligands, thereby enhancing T cell activation and anti-tumor immunity. Furthermore, LAG3-Fc has potential therapeutic applications in combination with other checkpoint inhibitors such as PD-1/PD-L1 therapies, aiming to improve clinical outcomes in cancer patients. Understanding the structure-function relationship of LAG3 and the design of effective recombinant proteins is vital for harnessing its immunomodulatory effects and advancing cancer therapies. Researchers are investigating the mechanisms by which LAG3 influences immune responses and exploring its use in various diseases, including autoimmune disorders, highlighting the importance of LAG3 research in developing innovative therapeutic strategies.